Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles

Vaccine

Volumn 28, Issue 50, 2010, Pages 7963-7969

  Saluja, V ^a   Visser, M R ^a   ter Veer, W ^b   van Roosmalen, M L ^c   Leenhouts, K ^c   Hinrichs, W L J ^a   Huckriede, A ^b   Frijlink, H W ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Mucosis BV   (Netherlands)

Author keywords

Adjuvant; Gram positive enhancer (GEM) matrix particles; Influenza; Vaccine

Indexed keywords

ADJUVANT; GRAM POSITIVE ENHANCER MATRIX PARTICLE; INFLUENZA VACCINE; PEPTIDOGLYCAN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HEMAGGLUTINATION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNIZATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; LACTOCOCCUS LACTIS; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, SUBUNIT; VIRAL LOAD;

EID: 78650244225     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.066     Document Type: Article

References (42)

1. CDC estimates of 2009 H1N1 influenza cases, hospitalizations and deaths in the United States. April 2009-February 13, 2010. Atlanta: Centers for Disease Control and Prevention, 2010 []. http://flu.gov/individualfamily/about/h1n1/estimates_2009_h1n1.html.
2. Couch R.B., Kasel J.A., Glezen W.P., Cate T.R., Six H.R., Taber L.H., et al. Influenza: its control in persons and populations. J Infect Dis 1986, 153(March (3)):431-440.
3. Cox R.J., Brokstad K.A., Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004, 59(January (1)):1-15.
4. Minor P.D. Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production. Clin Infect Dis 2010, 50(February (4)):560-565.
5. Ellebedy A.H., Webby R.J. Influenza vaccines. Vaccine 2009, 27(November (Suppl. 4)):D65-D68.
6. Hoelscher M., Gangappa S., Zhong W., Jayashankar L., Sambhara S. Vaccines against epidemic and pandemic influenza. Expert Opin Drug Deliv 2008, 5(October (10)):1139-1157.
7. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30(January (1)):23-32.
8. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004, 82(October (5)):497-505.
9. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998, 32(July (3)):155-172.
10. Middleton D., Rockman S., Pearse M., Barr I., Lowther S., Klippel J., et al. Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J Virol 2009, 83(August (15)):7770-7778.
11. Nolan T., Richmond P.C., Formica N.T., Hoschler K., Skeljo M.V., Stoney T., et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008, 26(November (50)):6383-6391.
12. Lau Y.F., Tang L.H., McCall A.W., Ooi E.E., Subbarao K. An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza vaccine with antigen-sparing effect in mice. J Virol 2010, (June):10.
13. Baras B., Stittelaar K.J., Simon J.H., Thoolen R.J., Mossman S.P., Pistoor F.H., et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 2008, 3(1):e1401.
14. Caillet C., Piras F., Bernard M.C., de Montfort A., Boudet F., Vogel F.R., et al. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice. Vaccine 2010, 28(April (18)):3076-3079.
15. Waddington C.S., Walker W.T., Oeser C., Reiner A., John T., Wilkins S., et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010, 340:c2649.
16. Keitel W.A., Campbell J.D., Treanor J.J., Walter E.B., Patel S.M., He F., et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis 2008, 198(November (9)):1309-1316.
17. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357(June (9272)):1937-1943.
18. Bodewes R., Kreijtz J.H., van Amerongen G., Geelhoed-Mieras M.M., Verburgh R.J., Heldens J.G., et al. A single immunization with CoVaccine HTTM-adjuvanted H5N1 influenza vaccine induces protective cellular and humoral immune responses in ferrets. J Virol 2010, 84(August (16)):7943-7952.
19. Brady R.C., Treanor J.J., Atmar R.L., Keitel W.A., Edelman R., Chen W.H., et al. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 2009, 27(August (37)):5091-5095.
20. Keitel W.A., Atmar R.L. Vaccines for pandemic influenza: summary of recent clinical trials. Curr Top Microbiol Immunol 2009, 333:431-451.
21. van Roosmalen M.L., Kanninga R., El Khattabi M., Neef J., Audouy S., Bosma T., et al. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. Methods 2006, 38(February (2)):144-149.
22. Bosma T., Kanninga R., Neef J., Audouy S.A., van Roosmalen M.L., Steen A., et al. Novel surface display system for proteins on non-genetically modified gram-positive bacteria. Appl Environ Microbiol 2006, 72(January (1)):880-889.
23. Audouy S.A., van Roosmalen M.L., Neef J., Kanninga R., Post E., van Deemter M., et al. Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization. Vaccine 2006, 24(June (26)):5434-5441.
24. Audouy S.A., van Selm S., van Roosmalen M.L., Post E., Kanninga R., Neef J., et al. Development of lactococcal GEM-based pneumococcal vaccines. Vaccine 2007, 25(March (13)):2497-2506.
25. Ramirez K., Ditamo Y., Rodriguez L., Picking W.L., van Roosmalen M.L., Leenhouts K., et al. Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection. Mucosal Immunol 2010, 3(March (2)):159-171.
26. Ramasamy R., Yasawardena S., Zomer A., Venema G., Kok J., Leenhouts K. Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations. Vaccine 2006, 24(May (18)):3900-3908.
27. Saluja V., Amorij J.P., van Roosmalen M.L., Leenhouts K., Huckriede A., Hinrichs W.L., et al. Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. AAPS J 2010, 12(June (2)):109-116.
28. Amorij J.P., Meulenaar J., Hinrichs W.L., Stegmann T., Huckriede A., Coenen F., et al. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 2007, 25(August (35)):6447-6457.
29. Bungener L., Geeraedts F., Ter Veer W., Medema J., Wilschut J., Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 2008, 26(May (19)):2350-2359.
30. The European Agency for the Evaluation of Medicinal Products (EMEA) Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonization of requirements for influenza vaccines. CPMP/BWP/214/96, London, March 12; 1997.
31. Amorij J.P., Saluja V., Petersen A.H., Hinrichs W.L., Huckriede A., Frijlink H.W. Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine 2007, 25(December (52)):8707-8717.
32. Hehme N., Colegate T., Palache B., Hessel L. Influenza vaccine supply: building long-term sustainability. Vaccine 2008, 26(September (Suppl. 4)):D23-D26.
33. Atmar R.L., Keitel W.A. Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol 2009, 333:323-344.
34. Hovden A.O., Cox R.J., Madhun A., Haaheim L.R. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scand J Immunol 2005, 62(October (4)):342-352.
35. Huber V.C., McKeon R.M., Brackin M.N., Miller L.A., Keating R., Brown S.A., et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 2006, 13(September (9)):981-990.
36. Tamura S., Kurata T. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 2004, 57(December (6)):236-247.
37. Yoshimura A., Lien E., Ingalls R.R., Tuomanen E., Dziarski R., Golenbock D. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 1999, 163(July (1)):1-5.
38. Brull F., Mensink R.P., van den Hurk K., Duijvestijn A., Plat J. TLR2 activation is essential to induce a Th1 shift in human peripheral blood mononuclear cells by plant stanols and plant sterols. J Biol Chem 2010, 285(January (4)):2951-2958.
39. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007, 5(July (7)):505-517.
40. Babai I., Barenholz Y., Zakay-Rones Z., Greenbaum E., Samira S., Hayon I., et al. A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. Vaccine 2001, 20(November (3-4)):505-515.
41. Chang S., Warner J., Liang L., Fairman J. A novel vaccine adjuvant for recombinant flu antigens. Biologicals 2009, 37(June (3)):141-147.
42. Hartikka J., Bozoukova V., Yang C.K., Ye M., Rusalov D., Shlapobersky M., et al. Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines. Vaccine 2009, 27(October (46)):6399-6403.